Picture of Xvivo Perfusion AB logo

XVIVO — Xvivo Perfusion AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMid CapFalling Star

Sweden's Xvivo beats Q4 sales expectations, posts 10% organic growth

Overview

Swedish medical tech firm's Q4 net sales beat analyst expectations

Organic growth driven by recovery in lung and strong liver and kidney performance

Company signed partnership with Perfusion Solution Inc to expand U.S. services

Outlook

Xvivo plans to expand U.S. operations in 2026

Company prepares for 2027 product launch of Heart Assist Transport

Xvivo sees strong development in liver and kidney segments

Result Drivers

ABDOMINAL BUSINESS - Co reported 30% sales growth in the Abdominal business area in local currencies

SERVICES DECLINE - Services segment saw a 21% decrease due to reduced organ recovery volumes

CURRENCY IMPACT - Net profit affected by currency effects in cash and cash equivalents

Key Details

MetricBeat/MissActualConsensus Estimate
Q4 SalesBeatSEK 226.10 mlnSEK 210.77 mln (3 analysts)
Q4 EPSSEK 1.01
Q4 Net IncomeSEK 31.60 mln
Q4 EBITSEK 36.80 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell" The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy" Wall Street's median 12-month price target for Xvivo Perfusion AB is SEK310.00, about 41.7% above its January 26 closing price of SEK218.80 The stock recently traded at 59 times the next 12-month earnings vs. a P/E of 40 three months ago Press Release: ID:nMFN2LNDsf For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Xvivo Perfusion AB

See all news